Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-08-07 08:00 |
Cellectis nomme le docteur Adrian Kilcoyne directeur médical
|
French | 147.6 KB | ||
| 2024-08-07 08:00 |
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
|
English | 156.9 KB | ||
| 2024-08-06 22:30 |
Cellectis publie ses résultats financiers du deuxième trimestre 2024
|
French | 638.5 KB | ||
| 2024-08-06 22:30 |
Cellectis Provides Financial Results for the Second Quarter 2024
|
English | 603.5 KB | ||
| 2024-08-05 22:30 |
Monthly information on share capital and company voting rights
|
English | 91.0 KB | ||
| 2024-08-05 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 120.8 KB | ||
| 2024-08-01 22:30 |
La FDA accorde le statut de médicament orphelin à CLLS52 (alemtuzumab) de Celle…
|
French | 66.2 KB | ||
| 2024-08-01 22:30 |
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL T…
|
English | 74.8 KB | ||
| 2024-07-25 22:30 |
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellect…
|
English | 196.7 KB | ||
| 2024-07-25 22:30 |
La FDA accorde le statut de médicament orphelin et médicament pour une maladie …
|
French | 210.1 KB | ||
| 2024-07-05 22:30 |
Monthly information on share capital and company voting rights
|
English | 92.0 KB | ||
| 2024-07-05 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 121.0 KB | ||
| 2024-06-28 22:30 |
Résultats de l’Assemblée Générale Mixte de Cellectis du 28 juin 2024
|
French | 88.7 KB | ||
| 2024-06-28 22:30 |
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
|
English | 98.5 KB | ||
| 2024-06-20 22:30 |
Cellectis publie un article scientifique dévoilant trois facteurs clés pour une…
|
French | 53.7 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
